Bengaluru : A suspected large-scale counterfeit medicine racket in Bengaluru has raised serious concerns over patient safety after investigators found that fake cancer medicines and other critical drugs had allegedly been supplied to more than 90 hospitals and clinics across the city.
The Bengaluru Police Special Investigation Team (SIT), working with the Drugs Control Department, arrested pharmacy owner Veeresh Kumar Jain in connection with the alleged racket. Investigators reportedly seized a substantial quantity of suspected counterfeit medicines during a raid on Krupa Healthcare, a pharmacy near Minerva Circle.
The case has drawn particular concern because the medicines allegedly included cancer drugs, life-saving medicines and injections used in intensive care units. Authorities are continuing to investigate the wider supply network and determine the extent to which the suspected counterfeit medicines entered the healthcare system.
Pharmacy allegedly used as distribution centre
According to the investigation reported by The Indian Express, Krupa Healthcare was allegedly being used as a storage and distribution point for the suspected counterfeit medicines.
Investigators suspect that medicines were subsequently supplied to medical shops, hospitals and clinics in Bengaluru.
The scale of the alleged distribution has become a major concern, with more than 90 healthcare institutions reportedly receiving medicines from the network.
Authorities are now examining the procurement and distribution chain to establish how the medicines reached healthcare facilities and whether additional individuals or businesses were involved.
The investigation was initiated after police received leads from an earlier case, eventually resulting in the raid on the pharmacy and the seizure of suspected counterfeit stock.
Expired medicines allegedly repackaged
Investigators have reportedly found evidence suggesting that the suspected operation involved more than simply selling medicines under false brand names.
According to the police investigation, low-cost medicines were allegedly rebranded and sold under different names. Expired medicines were also allegedly repackaged in new containers and given counterfeit labels resembling those of established pharmaceutical companies.
Such practices can create serious risks because patients, doctors and pharmacists may be unable to distinguish the products from genuine medicines based on their packaging.
The alleged use of counterfeit labels could also make tracing the original source of the medicines more difficult.
Authorities are expected to examine the seized products and relevant records as part of efforts to establish their composition, authenticity and intended distribution.
Cancer patients among those potentially at risk
The alleged supply of counterfeit cancer medicines is particularly alarming because patients undergoing cancer treatment often depend on carefully prescribed medicines as part of complex treatment plans.
The effectiveness, safety and correct dosage of medicines can be critical in such cases. A counterfeit or improperly stored medicine may fail to provide the intended treatment and could potentially expose patients to additional risks.
The reported involvement of ICU injections and other life-saving medicines has further heightened concerns.
At this stage, the investigation is focused on determining the nature of the suspected counterfeit products and where they were supplied. Authorities will also need to establish whether any patients were administered the medicines and whether adverse effects were reported.
Medicines allegedly sold at steep discounts
The investigation reportedly found that the suspected counterfeit medicines were offered at discounts of around 50 per cent.
Large discounts can make medicines attractive to buyers, particularly when the cost of genuine cancer and critical-care medicines is high.
However, unusually low prices can also warrant additional scrutiny, particularly when medicines are being procured through channels outside established pharmaceutical distribution networks.
The case highlights the importance of maintaining proper documentation and traceability throughout the pharmaceutical supply chain.
Hospitals and pharmacies need reliable systems for verifying suppliers, invoices, batch numbers, packaging and other details associated with medicines before they are distributed or administered to patients.
Investigation into wider network continues
The arrest of the pharmacy owner is only one part of the ongoing investigation.
The SIT and Drugs Control Department are expected to examine how the suspected medicines were sourced, where they were repackaged or relabelled and how they were distributed to healthcare establishments.
Investigators will also need to determine whether other pharmacies, distributors or intermediaries were knowingly involved.
The seizure of suspected counterfeit medicines provides investigators with evidence that can potentially help trace the network backwards to its source and forwards to the institutions that received the products.
Authorities may also examine financial transactions and supply records to establish the scale of the alleged operation.
Serious implications for healthcare safety
The case has raised broader questions about the need for stronger safeguards in the pharmaceutical supply chain.
Counterfeit medicines can undermine public confidence in healthcare systems and put vulnerable patients at risk. The danger becomes particularly serious when suspected fake products involve cancer treatment, emergency medicines or ICU drugs.
Hospitals and medical establishments are expected to procure medicines through authorised channels and maintain appropriate checks before accepting pharmaceutical products.
Patients, meanwhile, generally rely on doctors, hospitals and pharmacies to ensure that the medicines they receive are genuine and safe.
The alleged racket demonstrates how a breakdown in any part of the supply chain can have consequences far beyond the immediate businesses involved.
Authorities face task of tracing affected supplies
One of the most important tasks now is to identify all healthcare facilities that may have received the suspected counterfeit medicines.
If specific batches or products are confirmed to be counterfeit, authorities may need to trace and withdraw them from circulation to prevent further use.
Hospitals and pharmacies that received supplies from the alleged network may also be required to check their stocks and records.
The investigation could therefore have implications for a large number of medical establishments in Bengaluru.
For patients who may have received medicines from affected supplies, clear communication from the authorities and healthcare providers will be important once the investigation establishes which products and batches are involved.
Need for vigilance across the drug supply chain
The Bengaluru case serves as a stark reminder of the importance of pharmaceutical traceability.
From manufacturers and distributors to pharmacies and hospitals, each stage of the supply chain plays a role in ensuring that medicines reaching patients are authentic and safe.
The alleged circulation of counterfeit cancer medicines on such a large scale makes the investigation particularly significant.
As the SIT and Drugs Control Department continue their probe, authorities are expected to focus on identifying the full network behind the suspected racket, determining the quantity of counterfeit medicines distributed and assessing whether patients were affected.
The arrest of the pharmacy owner marks a significant development, but the wider investigation will be crucial in establishing accountability and preventing potentially dangerous medicines from reaching patients in the future.